Y
Yasmine Nivoix
Researcher at University of Strasbourg
Publications - 35
Citations - 1263
Yasmine Nivoix is an academic researcher from University of Strasbourg. The author has contributed to research in topics: Voriconazole & Aspergillosis. The author has an hindex of 15, co-authored 30 publications receiving 1105 citations.
Papers
More filters
Journal ArticleDOI
Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis
Yasmine Nivoix,Michel Velten,Valérie Letscher-Bru,Alireza Moghaddam,Shanti Natarajan-Amé,Cécile Fohrer,Bruno Lioure,Karin Bilger,Philippe Lutun,Luc Marcellin,Anne Launoy,Guy Freys,Jean-Pierre Bergerat,Raoul Herbrecht +13 more
TL;DR: Kohno et al. as discussed by the authors retrospectively reviewed 385 cases of suspected or documented aspergillosis that occurred during a 9-year period and identified 289 episodes that fulfilled the criteria for possible, probable, or proven invasive Aspergillus active antifungal drug treatment.
Journal ArticleDOI
Clinical pharmacokinetics of voriconazole
TL;DR: This review presents the published clinical pharmacokinetic data for the antifungal agent voriconazole and aspects regarding absorption, tissue distribution, elimination and kinetic interactions are discussed.
Journal ArticleDOI
The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals
Yasmine Nivoix,Dominique Levêque,Raoul Herbrecht,J.-C. Koffel,Laurence Beretz,Genevieve Ubeaud-Sequier +5 more
TL;DR: This review presents the published data on molecular determinants (enzymes, transporters, orphan nuclear receptors) of systemic triazole pharmacokinetics in humans, including itraconazoles, fluconazole, voriconazole and posaconazole.
Journal ArticleDOI
The lipid formulations of amphotericin B.
TL;DR: Liposomal amphotericin B is also indicated for empirical therapy of suspected fungal infections in febrile neutropenic patients giving this compound an advantage over the two other formulations.
Journal ArticleDOI
Invasive pulmonary aspergillosis.
TL;DR: Results of main trials assessing new antifungal agents in monotherapy or in combination are presented as well as the recommendations for their use according to international guidelines.